Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Eyes US Trastuzumab Potential As It Hits Profitability

Firm Recently Entered Crowded US Trastuzumab Market With Ontruzant

Executive Summary

In an exclusive interview, the executive vice-president for Samsung Bioepis’ commercial division, Sang-Jin Pak, tells Generics Bulletin there is plenty of opportunity remaining in the crammed US trastuzumab market and explains what an achievement it was for the South Korea-based company to reach profitability only eight years after inception.

You may also be interested in...



Samsung Bioepis Moves Eylea Biosimilar To Phase III

Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.

Coronavirus Boosts Biogen Biosimilars In First Quarter

Biogen reported more positive numbers for the firm’s biosimilars business in the first quarter of this year, although some of this growth was attributed to “accelerated sales” stemming from the COVID-19 pandemic. Meanwhile, the company revealed its latest thinking as it continues attempts to shield its key Tecfidera brand from competition in the US, following a fresh unfavorable patent ruling.

Fifth US Biosimilar To Herceptin Launched By Merck

Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel